At a glance
ClinicalIndex Comparison RecordN/ACompleted· 110 enrolled
Drug / intervention
Tocilizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Observe the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-biologic DMARD and/or Anti TNF Therapy.
In Brief
An observational study evaluating Tocilizumab for Rheumatoid Arthritis. Completed, enrolled 110 participants across 7 sites.
Detailed Summary
This observational study will evaluate the safety, tolerability and efficacy of tocilizumab in participants with moderate to severe RA who have an inadequate response to current non-biologic DMARD and/or anti-TNF therapy. Data will be collected from each participant during tocilizumab therapy and on follow-up for a total of 12 months.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesIndia
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2010
First PostedMay 2011
Primary CompletionJan 2015
TodayJul 2026
First PostedMay 27, 2011
Enrollment StartOct 26, 2010
Primary CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 15.1 years ago
Interventions
Tocilizumabdrug